ArticlePharmacogenomics2013
Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.
Article in Pharmacogenomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response.Journal of clinical laboratory analysis · 2022Pooled it
- Nonclinical human neural new approach methodologies (NAMs): Electrophysiological assessment of opioid agonist and antagonist combination.NAM journal · 2025Article
- Influence ofLife (Basel, Switzerland) · 2023Article
- Association of the D-amino acid oxidase gene with methadone dose in heroin dependent patients under methadone maintenance treatment.Journal of human genetics · 2022Article
- Pharmacogenomics of Opioid Treatment for Pain Management.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Pharmacogenetics of Addiction Therapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Dynamic Rhythmogenic Network States Drive Differential Opioid Responses in theThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- β-Arrestin 2 (ARRB2) Polymorphism is Associated With Adverse Consequences of Chronic Heroin Use.The American journal on addictions · 2021Article
- Identification of a sex-stratified genetic algorithm for opioid addiction risk.The pharmacogenomics journal · 2021Article
- Genetic Vulnerability to Opioid Addiction.Cold Spring Harbor perspectives in medicine · 2021Review
- Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway.Substance abuse treatment, prevention, and policy · 2021Article
- Influence ofJournal of pharmacy & bioallied sciences · 2020Article
- Pharmacogenomics of methadone: a narrative review of the literature.Pharmacogenomics · 2020Review
- Genetic variants in NECTIN4 encoding an adhesion molecule are associated with continued opioid use.PloS one · 2020Article
- Extreme sampling design in genetic association mapping of quantitative trait loci using balanced and unbalanced case-control samples.Scientific reports · 2019Article
- Effects of DRD2 splicing-regulatory polymorphism and DRD4 48 bp VNTR on crack cocaine addiction.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- GRK5 Is Associated with the Regulation of Methadone Dosage in Heroin Dependence.The international journal of neuropsychopharmacology · 2018Article
- Pharmacogenetics of Opioid Use Disorder Treatment.CNS drugs · 2018Review
- Pharmacogenetics of Methadone Response.Molecular diagnosis & therapy · 2018Review
- Methadone Dosage and Plasma Levels, SNPs of OPRM1 Gene and Age of First Drug Use Were Associated With Outcomes of Methadone Maintenance Treatment.Frontiers in genetics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
aimThe interindividual variability in the dose required for effective methadone maintenance treatment (MMT) for opioid addiction may be influenced in part by genetic variations in genes encoding pharmacodynamic factors of methadone. This study was conducted to identify some of these variants. MATERIALS &
methodsThis study focused on 11 genes encoding components of the opioidergic (OPRM1, POMC and ARRB2), the dopaminergic (ANKK1 and DRD2) and the glutamatergic pathways (GRIN1 and GRIN2A), as well as the neurotrophin system (NGFB, BDNF, NTRK1 and NTRK2). The study includes 227 Israeli patients undergoing stable MMT.
resultsOut of the 110 variants analyzed, 12 SNPs (in BDNF, NTRK2, OPRM1, DRD2 and ANKK1) were associated with methadone dose (nominal p < 0.05). Of these SNPs, ANKK1 rs7118900 and DRD2 rs2283265 are known to affect gene expression. Logistic regression of five representative SNPs discriminated between individuals requiring a methadone dose of >120 mg/day and <120 mg/day (p = 0.019), and showed moderate sensitivity and specificity (AUC of 0.63 in receiver operating characteristic analysis).
conclusionThis data should stimulate further research on the potential influence and clinical significance of these variants on MMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.